Background. Characteristics, associated factors, and survival probability of toxoplasmic encephalitis (TE) in the era of advanced highly active antiretroviral therapy (HAART) have not been fully clarified.
counts [3] . In the years 1992-1996, because of the widespread use of prophylactic regimens, a decrease in epidemiological trends of disease was observed [3] [4] [5] .
The advent of HAART has resulted in a reduction in the incidence of most opportunistic infections [6] [7] [8] and also in the incidence of CNS disorders, as confirmed by a recent European cohort study [5, [9] [10] [11] . Concerning TE, a trend towards a decreased incidence rate in the first years in which HAART was widely available, compared with the pre-HAART years, was reported in 2 large cohort studies [5, 12] . Of note is that TE prevalence among AIDS-related focal brain disorders appeared to stabilize during the HAART era, after a decrease was observed during the pre-HAART period [9] .
Before the availability of HAART, injection drug use, previous AIDS-defining events, decreased CD4 + cell count, lack of antiretroviral therapy, and lack of prophylaxis against infection with Toxoplasma species were all reported as being significantly associated with an increased risk of developing TE [3, 12] . At the beginning of the HAART era, lack of exposure to HAART and prophylaxis, as well as persistent CD4
+ cell depletion, significantly increased the risk of disease [12] .
The proportion of TE-associated deaths decreased from 3.5% of all HIV infection-related deaths in 1992 to 1.9% in 1998, with a percentage reduction greater than that observed in HIVrelated deaths overall [13] . Although the improvement in survival of HIV-infected patients due to HAART has largely been documented [14] [15] [16] , specific evaluations about survival and associated factors in HIV-infected patients with TE have not been carried out until now.
The aim of the present study was to assess prevalence, clinical characteristics, and survival probability of patients with newly diagnosed cases of TE in the advanced HAART era. Moreover, the relationship between occurrence of TE and previous exposure to antiretroviral therapy and prophylaxis against infection with Toxoplasma species was evaluated.
METHODS
Design of the study and diagnostic criteria. The Italian Registry Investigative NeuroAIDS (IRINA) study is a prospective multicenter study that involves 45 Italian infectious diseases centers that specialize in the treatment of HIV-infected patients. The main aim of the survey is to analyze epidemiological changes in and document the natural history of HIV-related neurological disorders in the era of HAART. The second aim of the IRINA study is to evaluate survival probability, baseline values, and longitudinal survival-associated factors in relationship to antiretroviral exposure before and after diagnosis of neurological disorders [17] . The study started in January 2000 and included all patients with HIV-related disorders of the CNS who were consecutively observed in the participating centers. For each case of neurological disease, the center is required to fill out a notification sheet with data that includes demographic and epidemiological variables, history of HIV infection and receipt of antiretroviral therapy, clinical and radiological characteristics, and diagnostic criteria. Every 6 months, a followup sheet is filled out with information regarding treatment outcome and survival.
Statistical analysis. The current study was based on all cases documented as part of the IRINA study from January 2000 through December 2002. To avoid selection bias, the analysis was restricted to persons experiencing a first episode of TE and to those with р1 concomitant CNS disorder. Diagnosis of TE was performed in agreement with the 1993 Centers for Disease Control and Prevention (CDC) classification, and both histological and presumptive diagnoses were accepted. Presumptive diagnosis was based on compatible clinical and/or neuroradiological signs, serological test results positive for Toxoplasma species, or response to specific therapy [18] .
The association between the presence of TE and demographic, clinical, and radiological characteristics was explored by contingency tables and was estimated calculating ORs 2 ϫ 2 with 95% CIs. Statistical significance was tested by Fisher's exact test or by univariate logistic regression analysis. A multivariable logistic regression model that included all significant covariates found by univariate analysis was used to calculate adjusted ORs and to detect factors predictive of TE.
To analyze the effect of exposure to antiretroviral therapy, patients were stratified in 2 groups according to exposure to antiretroviral treatment. The first group included patients who were antiretroviral therapy naive at TE diagnosis, and the second group included patients who were receiving HAART at TE diagnosis or had experienced antiretroviral therapy. Differences between the 2 groups were assessed using 1-way analysis of variance or Fisher's exact test and logistic regression, as appropriate, for continuous and categorical variables, respectively. Survival probabilities were estimated using the Kaplan-Meier method and log-rank test. A Cox proportional hazards model was employed to define crude and adjusted relative hazards associated with death and clinical progression of disease. The multivariable model was adjusted for baseline and time-dependent covariates that significantly influenced survival and clinical progression on univariate analysis. All P values р.05 were considered to be statistically significant. Statistical analysis was performed using the software package SPSS, version 11.0.1 (SPSS). [18] , was obtained in 95.6%. Neuroimaging diagnosis was made on the basis of CT and MRI findings in 66 (32.2%) of the patients, CT findings alone in 97 (47.3%), and MRI findings alone in 42 (20.5%). Of the 568 patients classified as not having TE, only 67 (11.8%) had a mass effect, and 56 of these patients received a diagnosis of an alternative CNS disorder that was confirmed by accepted criteria. In particular, the diagnoses were progressive multifocal leukoencephalopathy (5 cases), primary CNS lymphoma (26) , cytomegalovirus encephalitis (1), cerebral criptococcosis (6), CNS tuberculosis (4), and systemic nonHodgkin lymphoma with CNS involvement (5); 9 other disorders were diagnosed, including neurosyphilis (1 case), meningiomas (2), intracerebral hematoma (2), brain astrocitoma (2), and pyogenic abscess (2). In the remaining 11 patients, an encephalopathy of unknown origin, defined by the absence of diagnostic criteria for the other disorders and by a defined neuroradiological pattern, was described. Of these 11 patients, 5 had a CD4 + cell count of у200 cells/mL and a neuroimaging pattern not suggestive of TE. Of the remaining 6 patients with CD4 + cell counts of !200 cells/mL, only 2 had serological test results positive for Toxoplasma species; however, in both cases, TE has been reasonably excluded on the basis of clinical and radiological findings and follow-up. Comparisons between the demographic, clinical, virological, and neuroradiological characteristics of patients with TE and patients without TE are reported in table 1.
RESULTS

Prevalence
Baseline demographic, epidemiological, virological, clinical, and radiological features for all patients, stratified according to previous exposure to antiretroviral therapy, are reported in table 2. Previous exposure to antiretroviral therapy was found in 76 (36%) of the patients. Among patients who had experienced antiretroviral therapy, 10 (13%) had received nucleoside reverse-transcriptase inhibitor monotherapy or double therapy, with a median duration of exposure of 9 months (interquartile range (IQR), 2-24 months), and 66 (87%) had received HAART, with a median duration of exposure of 24 months ([IQR], 6-45 months). At neurological diagnosis, 44 (66%) of the patients were receiving HAART, and 22 (34%) had discontinued antiretroviral therapy. Virological parameters strongly differed between the antiretroviral therapy-experienced and the antiretroviral therapy-naive groups (table 2). Among patients in the experienced group, an undetectable virus load in plasma and a CD4 + cell count 1200 cells/mL at TE diagnosis were found in 11% and 12% of patients, respectively. Patients in the ex- perienced group identified injection drug use as the HIV transmission route more frequently (OR, 2.00; 95% CI, 1.11-3.59), were more likely to have experienced a previous AIDS-defining event (OR, 12.70; 95% CI, 6.01-26.82), and were more likely to have been exposed to prophylaxis against TE (OR, 6.07; 95% CI, 2.71-13.58). Prevalence of TE, stratified according to exposure to antiretroviral therapy, as well by CD4 + cell count and virus levels in plasma, is shown in figure 1 .
Factors associated with TE. The relationship between the risk of developing TE and different baseline factors is shown in table 3. Male sex, previous exposure to antiretroviral therapy, and higher CD4 + cell count at neurological diagnosis significantly decreased the probability of TE according to multivariate logistic regression analysis. The presence of lesions with contrast enhancement or with mass effect was associated with a significantly higher risk of TE diagnosis, and detection of white matter abnormalities was related to a decreased risk of disease. Age, HIV transmission route, previous diagnosis of AIDS, plasma HIV RNA load, and neurological features did not affect the risk of TE occurrence.
TE prophylaxis was received by 35 (17%) of 205 patients. Of note, as many as 31 (66%) of 47 patients who had experienced antiretroviral therapy and who had CD4 + cell counts of !100 cells/mL were not receiving prophylaxis at the time of TE diagnosis, even though 54% of them were currently prescribed HAART. As shown in table 3, receipt of TE prophylaxis independently reduced the risk of developing TE in the multivariate model. TE follow-up. During the first 6 months after TE diagnosis, the median duration of exposure to HAART was 150 days (IQR, 79-180 days). At 6 months, improvement and/or resolution of disease was observed in 76% of patients during clinical examination and in 73.2% of patients according to CT and MRI findings. The 6-month mean (‫ע‬SD) change in HIV RNA load was Ϫ log 10 copies/mL, and the mean (‫ע‬SD) increase 2.1 ‫ע‬ 1.7 in CD4 + cell count was cells/mL ( On multivariable logistic regression analysis, the probability of achieving 6-month clinical improvement and/or resolution of disease was significantly lower in the antiretroviral therapyexperienced patients than in the antiretroviral therapy-naive patients (OR, 0.25; 95% CI, 0.16-0.39), even after adjusting for CD4 + cell count, HIV RNA load, abnormal mental status, number of brain lesions, prophylaxis against Toxoplasma species, and duration of exposure to HAART after TE diagnosis. Survival analysis. After a median follow-up period of 365 days (IQR, 180-545 days), a total of 34 patients (16.1%) died, and 25 (73.5%) of these patients died during the first 6 months of follow-up. In 22 cases, death was related to TE. During follow-up, there were 24 patients who experienced new AIDSdefining events. The 1-year probability of clinical progression of disease (i.e., the probability of experiencing a new AIDSrelated event or death) was 40%. According to the multivariate Cox model, only the presence of cognitive symptoms was independently associated with an increased risk of HIV-related disease progression, whereas a CD4 + cell count у100 cells/mL and receipt of HAART after TE diagnosis (a time-dependent covariate) were both associated with a reduced risk (table 5) . According to multivariate Cox regression, patients who initiated HAART within 2 months after TE diagnosis had a significantly decreased probability of HIV-associated disease progression, compared with those who delayed therapy (relative hazard, 0.36; 95% CI, 0.15-0.86).
The 1-year estimated survival probability after TE diagnosis was 77%. Analyzing the risk of death with use of the multivariable Cox model, the presence of abnormal mental status was the only variable that was independently associated with an increase in the risk of death, and receipt of HAART after diagnosis was the only factor that was independently associated with a decrease in the risk of death (table 5). Kaplan-Meier curves displaying the probability of progression to AIDS or death and to death alone according to prognostic variables are shown in figure 2.
DISCUSSION
The results of our study indicate that, even in the late HAART era, TE is still the most prevalent CNS disorder, accounting for approximately one-fourth of all documented cases in both antiretroviral-treated and untreated HIV-infected persons. This is in accordance with the finding that the prevalence of this disorder among patients with focal brain lesions has remained unchanged since the first years of the HAART era [9] , even though a reduction of incidence has been reported [5, 12] . This apparent discordance between prevalence data and incidence data may be accounted for by a smaller decrease in the incidence of TE, compared with other neurological disorders [5] . Considering that 36% of TE episodes occurred in persons with previous exposure to antiretrovirals, patients who had experienced antiretroviral therapy had a 50% reduction in risk of developing TE. This effect was independent of HIV RNA load and CD4
+ cell count, confirming that the protective effect of HAART against clinical progression is not simply related to virological success [19] . Nevertheless, plasma virus levels were comparably high and CD4 + cell count was consistently low both in antiretroviral-naive and in antiretroviral-experienced patients, suggesting that the failure of treatment with antiretrovirals is the main determinant when TE occurs in patients receiving HAART. The fact that only 25% of patients developed TE during the first 6 months of HAART (data not shown) seems to suggest that the early risk due to incomplete recovery of the immune system [20, 21] might not have represented a relevant issue in our cohort.
A recent large prospective cohort study [12] showed that lack of exposure to antiretroviral therapy and immunosuppression markers were strong predictors of TE occurrence. In the present study, we found that, for each 50-cell decrease in CD4 + cell count, there was a 30% increase in the risk of TE occurrence, independent of antiretroviral exposure. It has been suggested that a reduced risk of TE in the presence of HAARTinduced recovery of the immune system is associated with a restoration of specific immune responses against Toxoplasma gondii [22] . This observation has relevant implications for therapeutic strategies, in particular for patients who remain strongly immunodeficient despite HAART and are therefore still susceptible to opportunistic infections [12, 23] .
The efficacy of primary prophylaxis in preventing TE is well known [24] [25] [26] . In a comparative study by calendar years [12] , primary prophylaxis reduced the risk of TE by 46% in the early HAART era. The present study confirmed the efficacy of primary prophylaxis in prevention of TE, with a 53% reduction of the risk of TE occurrence. These results emphasize that, even in the era of HAART, TE prophylaxis will remain a main factor in reducing disease occurrence [8, 27] . Prophylaxis should be discontinued in HAART-treated patients only when a sustained rise in CD4 + cell count is detected [8, [28] [29] [30] [31] [32] ; we observed that only 34% of antiretroviral-experienced patients with a CD4 + cell count !100 cells/mL were receiving TE prophylaxis at diagnosis. On the basis of these data, survey studies about physician adherence to guidelines for the prevention of opportunistic infections in the HAART era may be advisable.
We could not entirely account for the increased risk of TE observed in women independent from HAART exposure, virological markers, and TE prophylaxis. Female sex has been associated with lower HIV loads in plasma, but significant sexbased differences in rates of disease progression have been excluded [33, 34] . Furthermore, a higher rate of discontinuation of therapy because of toxicity or likely poor adherence was observed in HIV-infected women starting antiretroviral therapy [35] , even though sex was not generally associated with adherence to HAART in most studies [36] . Female sex as a factor increasing the risk of TE should be elucidated further.
Survival analysis showed that TE occurrence still represents a poor prognostic determinant in the natural history of HIVinfected persons, even in the era of HAART. In our cohort, the estimated 1-year probabilities of showing HIV disease progression or death were 40% and 23%, respectively. This finding is consistent with that observed among patients with AIDS and multiple adverse prognostic factors in a large cohort of antiretroviral-naive patients starting HAART [37] . It is reasonable to assume that, even though HAART remains the main prognostic determinant in patients with advanced disease and severe immunodeficiency [15, 38] , TE-specific mortality had a relevant role in negatively affecting survival, accounting for more than two-thirds of all deaths. However, in our study, starting HAART after TE diagnosis was associated with a strong reduction of the risk of clinical progression of disease and death, and this is consistent with the dramatic improvement in survival rates observed in patients with advanced disease when adjusted for HAART adherence and appropriate care [39] . Considering the calendar years of the present study, it is conceivable that our cohort could have benefited from the improvements in antiretroviral regimens and HAART management that have been observed in recent years for HIV-infected persons with very advanced disease [40] .
We further observed a significant benefit of early initiation of HAART after TE diagnosis. In fact, a 3-fold reduction in the risk of developing a new AIDS-defining event or death in patients who started HAART within the first 2 months after diagnosis of a neurological disorder has been found. An unresolved question, raised in the past several years, concerned the appropriate timing for initiation of HAART in patients with opportunistic diseases. Even though a potential benefit in treating certain AIDS-related conditions has been shown [41, 42] , relevant concerns relative to the toxicity of multiple-drug regimens and poor adherence have supported delaying the initiation of HAART until after the acute phase of most opportunistic diseases. Even though we are not able to determine the optimum timing for starting HAART after TE diagnosis, it seems that early initiation of HAART leads to a survival benefit.
Some limitations of this study need to be mentioned. First, classification bias could not be entirely excluded because TE diagnoses were formulated by the treating physician at the participating center. However, diagnostic criteria were standardized in the study design, according to updated literature, and the methods that were employed were specified in each notification sheet. The Coordinating Center revised all notified sheets and certified the appropriate definition criteria employed, and all discordant cases were excluded. A second limitation of the study was that information about serological testing for Toxoplasma species was only included among the diagnostic criteria of TE and was not specifically required on the notification sheet for other diagnoses. The lack of this finding may have affected a complete evaluation of prophylaxis data. Nevertheless, previous data showed that only 3%-6% of patients with TE had negative results of serological tests [43] , and this could have minimized possible bias in the analysis. Furthermore, previous data suggest that, in the Italian population, the rate of primary infection with Toxoplasma species did not increase as a result of an increase in the rate of AIDS [44] , as confirmed by the very low prevalence of detection of IgM-specific antibody response in HIV-infected people. On the basis of these considerations, we think that a lack of serological testing for infection with Toxoplasma species would not have significantly influenced the accuracy of the epidemiological data in our study.
Finally, we cannot estimate the exact prognostic impact of TE on survival because of a lack of control subjects with advanced HIV infection who did not have neurological disease. However, prevalent data allow more-accurate comparative analyses within a group of subjects who are homogeneous for clinical selection criteria, and this method is more appropriate for acquiring clinical information.
In conclusion, TE remains the most prevalent cause of HIVassociated neurological disorders, even in the late HAART era, with an increased risk of disease observed in antiretroviral-naive patients. Severe immunodeficiency and a lack of TE prophylaxis were confirmed as main determinants of TE occurrence, independent of whether HAART was received. Moreover, even if receipt of HAART after diagnosis with a neurological disorder markedly reduced the risk of clinical progression and deathparticularly if started early in the course of neurological disease-TE survival remained poor, mainly for early specific mortality. Because TE was associated with a high probability of early death, all strategies to avoid TE occurrence, such as not delaying HAART until there is a high risk of clinical progression and maintaining prophylaxis in immunosuppressed patients for whom HAART has failed, should be considered [45] [46] [47] .
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